Mendelian randomization (MR) permits the study of genetic variation unaffected by socioeconomic, environmental, and behavioral confounders. Single nucleotide polymorphisms pertinent to IBD (including ...

A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver ...

Primary sclerosing cholangitis (PSC) is a chronic, progressive inflammatory disease characterized by fibrosis and bile duct ...

Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment options ...

A new monoclonal antibody treatment has shown promising results for a rare liver disease called primary sclerosing ...

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel ...

Sclerosing cholangitis and primary biliary cirrhosis, which is now called primary biliary cholangitis (PBC), are chronic cholestatic liver diseases, but they differ in their causes, affected bile ...

Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease of uncertain etiology characterized by the destruction of the intrahepatic and/or extrahepatic ducts through ...

LONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Yaqrit, a late clinical-stage company developing life-saving treatments for advanced liver diseases, announced today that the first patient has been treated ...

Please provide your email address to receive an email when new articles are posted on . The liver’s production of bile acids is interwoven with the gut’s diverse microbial community. Despite treatment ...